Patent DE897942C successfully refreshed from Google Patents.
Patent US5156949A successfully refreshed from Google Patents.
US5156949A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunoassays for antibody to human immunodeficiency virus using recombinant antigens
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1987-12-24
•
Granted: 1992-10-20
•
Expires: 2007-12-24
Abstract
Abstract Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Inventors
- 👤 Paul A. Luciw
- 👤 Dino Dina
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 21:25
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P37/00; A61P37/02; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/80; C12N15/81; C12N15/85; C12N9/00; C12N9/0004; C12N9/0089; C12Q; C12Q1/00; C12Q1/70; C12Q1/701; C12Q1/702; C12Q1/703; A61K; A61K38/00; C07K2319/00; C07K2319/40; C07K2319/70; C07K2319/735; C07K2319/74; C07K2319/75; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16111; C12N2740/16122; C12N2740/16211; C12N2740/16222; C12N2800/00; C12N2800/10; C12N2800/108; C12N2830/00; C12N2830/001; C12N2830/002; C12N2830/005; C12N2830/15; C12N2830/36; C12N2830/55; C12N2830/70; C12N2830/702; C12N2830/704; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/82; Y10S435/8215; Y10S435/948; Y10S435/974; Y10S435/975; Y10S530/00; Y10S530/82; Y10S530/826
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
100 words
In an immunoassay to detect the presence of antibodies to a human immunodeficiency virus (HIV) in a human sample comprising contacting said sample with an immunogenic polypeptide comprising an amino acid sequence from the envelope (env) domain of said HIV and determining whether antibodies are bound to said immunogenic polypeptide, the improvement comprising employing as said immunogenic polypeptide a recombinant polypeptide that is the expression product of cellular hosts transformed by a heterologous expression vector comprising a DNA sequence encoding said recombinant polypeptide under the control of transciptional and translational initiation and termination regulatory sequences functional in said cellular hosts.
Claim 2
Dependent Claim
100 words
In an immunoassay to detect the presence of antibodies to a human immunodeficiency virus (HIV) in a human sample comprising contacting said sample with an immunogenic polypeptide comprising an amino acid sequence from the envelope (env) domain of said HIV and determining whether antibodies are bound to said immunogenic polypeptide, the improvement comprising employing as said immunogenic polypeptide a recombinant polypeptide that is the expression product of cellular hosts transformed by a heterologous expression vector comprising a DNA sequence encoding said recombinant polypeptide under the control of transciptional and translational initiation and termination regulatory sequences functional in said cellular hosts.
Claim 3
Independent Claim
119 words
A method of detecting antibodies to a human immunodeficiency virus (HIV) in a human sample comprising: a) providing a solid support having bound thereto a recombinant polypeptide comprising at least an immunogenic portion of the envelope (env) domain of said HIV, wherein said recombinant polypeptide is the expression product of cellular hosts transformed by a heterologous expression vector comprising a DNA sequence encoding said recombinant polypeptide under the control of transciptional and translation initiation and termination regulatory sequences functional in said cellular hosts; b) contacting said solid support with said human sample to provide a sample-contacted support; c) washing said sample-contacted support to provide a washed support; and d) determining whether human antibodies are bound to said washed support.
Claim 4
Independent Claim
119 words
A method of detecting antibodies to a human immunodeficiency virus (HIV) in a human sample comprising: a) providing a solid support having bound thereto a recombinant polypeptide comprising at least an immunogenic portion of the envelope (env) domain of said HIV, wherein said recombinant polypeptide is the expression product of cellular hosts transformed by a heterologous expression vector comprising a DNA sequence encoding said recombinant polypeptide under the control of transciptional and translation initiation and termination regulatory sequences functional in said cellular hosts; b) contacting said solid support with said human sample to provide a sample-contacted support; c) washing said sample-contacted support to provide a washed support; and d) determining whether human antibodies are bound to said washed support.
Claim 5
Dependent Claim
10 words
The method claim 1 wherein said cellular hosts are microorganisms.
Claim 6
Dependent Claim
10 words
The method claim 2 wherein said cellular hosts are microorganisms.
Claim 7
Dependent Claim
11 words
The method of claim 3 wherein said microorganisms are E. coli.
Claim 8
Dependent Claim
11 words
The method of claim 4 wherein said microorganisms are E. coli.
Claim 9
Dependent Claim
11 words
The method of claim 3 wherein said microorganisms are S. cerevisiae.
Claim 10
Dependent Claim
11 words
The method of claim 4 wherein said microorganisms are S. cerevisiae.
Claim 11
Dependent Claim
12 words
The method of claim 1 wherein said cellular hosts are mammalian cells.
Claim 12
Dependent Claim
12 words
The method of claim 2 wherein said cellular hosts are mammalian cells.
Claim 13
Dependent Claim
12 words
The method of claim 1 wherein said recombinant polypeptide is not glycosylated.
Claim 14
Dependent Claim
12 words
The method of claim 2 wherein said recombinant polypeptide is not glycosylated.
Claim 15
Dependent Claim
11 words
The method of claim 1 wherein said human sample comprises serum.
Claim 16
Dependent Claim
11 words
The method of claim 2 wherein said human sample comprises serum.
Claim 17
Dependent Claim
33 words
The method of claim 2 wherein step (d) comprises contacting said washed support with labeled antibodies to human Ig and the specific binding of said labeled antibodies to said washed support is measured.
Claim 18
Dependent Claim
20 words
The method of claim 15 wherein said labeled antibodies bound to said washed support are measured by an enzyme label.
Claim 19
Dependent Claim
84 words
An article of manufacture adapted for use in an immunoassay for antibodies to a human immunodeficiency virus (HIV) comprising a solid support having bound thereto a recombinant polypeptide comprising at least an immunogenic portion of the envelope (env) domain of said HIV, wherein said recombinant polypeptide is the expression product of cellular hosts transformed by a heterologous expression vector comprising a DNA sequence encoding said recombinant polypeptide under the control of transciptional and translation initiation and terminator regulatory sequences functional in said cellular hosts.
Claim 20
Dependent Claim
84 words
An article of manufacture adapted for use in an immunoassay for antibodies to a human immunodeficiency virus (HIV) comprising a solid support having bound thereto a recombinant polypeptide comprising at least an immunogenic portion of the envelope (env) domain of said HIV, wherein said recombinant polypeptide is the expression product of cellular hosts transformed by a heterologous expression vector comprising a DNA sequence encoding said recombinant polypeptide under the control of transciptional and translation initiation and terminator regulatory sequences functional in said cellular hosts.
Claim 21
Dependent Claim
14 words
The article of manufacture of claim 17 wherein said recombinant polypeptide is not glycosylated.
Claim 22
Dependent Claim
13 words
The article of manufacture of claim 17 wherein said cellular hosts are microorganisms.
Claim 23
Dependent Claim
13 words
The article of manufacture of claim 19 wherein said microorganisms are E. coli.
Claim 24
Dependent Claim
13 words
The article of manufacture of claim 19 wherein said microorganisms are S. cerevisiae.
Claim 25
Dependent Claim
14 words
The article of manufacture of claim 17 wherein said cellular hosts are mammalian cells.
References Cited (Backward Citations)
EP0136798A2
Cited
US4708818A
Cited
EP0165120A1
Cited
EP0138667B1
Cited
EP0139216A2
Cited
EP0152030A2
Cited
US4520113A
Cited
WO1985004897A1
Cited
WO1985004903A1
Cited
US4716102A
Cited
EP0173529A1
Cited
EP0178978A1
Cited
EP0185444A2
Cited
WO1986002383A1
Cited
EP0181150B1
Cited
US4725669A
Cited
US4751180A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-10-20 | 1996-04-20 | 1996-10-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-10-20 | 2000-04-20 | 2000-10-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-10-20 | 2004-04-20 | 2004-10-20 | $7700.00 | Window Closed / Lapsed |